Novartis AG, of Basel, Switzerland, said Bexsero (meningococcal group B vaccine [rDNA, component, adsorbed]) received a clinical recommendation in Australia for the vaccine’s routine use to help against meningitis B. That recommendation joins recommendations across multiple regions in Europe.